A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

What Was Tested

The trial (phase 1) is built around Tirzepatide and Bimagrumab.

The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide.

Participation in the study will last about 4.5 months, including screening and follow-up.

It had five arms (groups): one (experimental), one (experimental), one (experimental), one (experimental) and one (experimental).

The registry classes the interventions as drug.

Who Took Part

The registry lists 125 actual participants took part.

It was open to people of any sex aged from 18 years up to 64 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Are considered healthy as determined by medical evaluation including medical history and physical examination. Have a body mass index (BMI) within the range of 22.0 to 30.0 kilograms per square meter (kg/m2), inclusive.

The full record lists 2 inclusion and 4 exclusion criteria; among the exclusions: have current or a history of pancreatitis or hepatitis; have uncontrolled high blood pressure; have taken medications or alternative remedies to promote weight loss within 3 months prior to screening.

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Everyone knew when Tirzepatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2025-03-25 with completion listed for 2025-09-26.

It ran at 1 site in United States.

Its stated primary purpose is basic science.

What Was Measured

Primary outcome: PK: Cmax of Bimagrumab Reference Material (time frame: Predose through Week 13). PK: Cmax of Bimagrumab Coadministered with Tirzepatide (time frame: Predose through Week 13). PK: Cmax of Tirzepatide Coadministered with Bimagrumab (time frame: Predose through Week 16).

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Tirzepatide and Bimagrumab in 125 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page and the Bimagrumab compound page, all human trials.